
CAR T-cell Therapy - Pipeline Insight, 2024
Description
CAR T-cell Therapy - Pipeline Insight, 2024
DelveInsight’s, “CAR T-cell Therapy - Pipeline Insight, 2024” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CAR T-cell Therapy: Overview
CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137. CAR T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. The effectiveness of CAR T-cell Therapy is based on antigen specificity of T-cells. This specificity can be enhanced by the genetic modification and redirection of T-cells to target antigens that are overexpressed in tumors. Patient’s T-cells can be engineered to express modified Chimeric Antigen Receptors (CARs) that will enhance antigen specificity.
""CAR T-cell Therapy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-cell Therapy pipeline landscape is provided which includes the disease overview and CAR T-cell Therapy treatment guidelines. The assessment part of the report embraces, in depth CAR T-cell Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-cell Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-cell Therapy R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-cell Therapy.
This segment of the CAR T-cell Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-cell Therapy Emerging Drugs
- JWCAR029: JW Therapeutics
- Descartes-11: Cartesian Therapeutics
- CNCT19: CASI Pharmaceuticals
- CTL119: Novartis
- P-BCMA-101: Poseida Therapeutics
- AUTO4: Autolus Limited
- Descartes-08: Cartesian Therapeutics
- ET140202: Eureka Therapeutics
- MB-102: Mustang Bio
- AU101: Aurora Biopharma
Further product details are provided in the report……..
CAR T-cell Therapy: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-cell Therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in CAR T-cell Therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- CAR-T cell therapies
- Immunotherapies
- Gene therapy
- Product Type
CAR T-cell Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-cell Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-cell Therapy drugs.
CAR T-cell Therapy Report Insights
- CAR T-cell Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR T-cell Therapy drugs?
- How many CAR T-cell Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-cell Therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-cell Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-cell Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sorrento Therapeutics
- Cartesian Therapeutics
- CASI Pharmaceuticals
- Novartis
- Poseida Therapeutics
- Shanghai Unicar-Therapy Bio-medicine Technology
- Sinobioway Cell Therapy Co., Ltd.
- Gilead Sciences
- Tessa Therapeutics
- Wuhan Bio-Raid Biotechnology
- Autolus Limited
- Beijing Immunochina Medical Science and Technology
- BioAtla
- BioInvent International
- Carsgen Therapeutics
- Chongqing Precision Biotech
- Eureka Therapeutics
- Formula Pharmaceuticals
- Guangzhou Bio-gene Technology
- Hebei Senlang Biotechnology
- Mustang Bio
- MolMed
- Aurora BioPharma
- Atara Biotherapeutics
- Bellicum Pharmaceuticals
- Kecellitics Biotech Company Ltd
- Yake Biotechnology
- Minerva Biotechnologies
- Shanghai GeneChem Co., Ltd.
- Allogene Therapeutics
- Miltenyi Biotec
- PersonGen BioTherapeutics (Suzhou)
- Precision BioSciences
- Takara Bio
- BioNTech
- Miltenyi Biomedicine
- CRISPR Therapeutics
- Celgene
- Cellectis
- Celyad
- Gracell Bio
- Servier
- Protheragen
- Noile-Immune Biotech
- Arcellx Inc
- HRAIN Biotechnology
- Tmunity Therapeutics Inc.
- AffyImmune Therapeutics
- Maxcyte
- Kuur Therapeutics
- TILT Biotherapeutics
- Targazyme
- TC BioPharm
- Takeda
- Sensei Biotherapeutics
- Sana Biotechnology
- Oncternal Therapeutics
- Humorigin
- Fate Therapeutics
- Enlivex Therapeutics Ltd
- Exuma
- Caribou Biosciences
- Arbele Limited
- Adicet Bio
- CEA CAR-T
- Descartes-11
- CNCT19
- CTL119
- P-BCMA-101
- EPCAM-targeted CAR-T cells
- KTE-X19
- TT11
- AUTO4
- AUTO3
- IM19 CAR-T
- CAB-AXL-ADC
- CAB-ROR2-ADC
- CSG-CD19
- CT053
- Descartes-08
- PCAR-19B
- BCMA CAR-T cells
- ET140202
- CIK-CAR.CD19
- BG-T19
- Autologous CD19-targeting CAR T cells (Senl-001)
- MB-102
- Autologous CAR-T CD44v6 cell therapy
- AU101
- ATA2271
- AUTO1
- BPX-601
- CD123 CAR T cell therapy
- Anti-CD22 CAR
- huMNC2-CAR44 CAR T-cells
- ALLO-501A
- AUTO1/22
- ET 1402L1-CART
- BPX-603
- MB CART 20.1
- MB-106
- PCAR-019
- Anti-MUC1 CAR-T cells
- PBCAR0191
- PBCAR269A
- TBI-1501
- BNT211
- MB-CART19.1
- iCarTAB BioMed
- CTX101
- Bluebird Bio
- bb21217
- JCAR 018
- UCART123
- CYAD-02
- GC027
- NIB-102
- TMUN ONC 001
- AIC100
- MCY-M11
- KUR-501
- TILT-T392
- TZ-102
Table of Contents
60 Pages
- Introduction
- Executive Summary
- CAR T-cell Therapy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- CAR T-cell Therapy – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- CAR T-cell Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- CAR T-cell Therapy Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
- Comparative Analysis
- JWCAR 029: JW Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Descartes-11: Cartesian Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- ET140202: Eureka Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- TT14: Tessa Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- CAR T-cell Therapy Key Companies
- CAR T-cell Therapy Key Products
- CAR T-cell Therapy- Unmet Needs
- CAR T-cell Therapy- Market Drivers and Barriers
- CAR T-cell Therapy- Future Perspectives and Conclusion
- CAR T-cell Therapy Analyst Views
- CAR T-cell Therapy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.